ESR1 and breast neoplasm: For this reason, understanding the oncogenic pathways responsible for the development of resistance to endocrine therapy given before or after primary surgery is imperative to develop innovative therapeutic strategies aimed to suppress or at least delay recurrence and progression of initially ERα+ breast tumors.